Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.

Clinical lymphoma, myeloma & leukemia - 1 Oct 2011

Almasi Martina, Sevcikova Sabina, Slaby Ondrej, Kaisarova Petra, Maisnar Vladimir, Penka Miroslav, Pika Tomas, Pour Ludek, Radocha Jakub, Scudla Vlastimil, Svachova Hana, Hajek Roman

Abstract excerpt

INTRODUCTION/BACKGROUND: Venous thromboembolism (VTE), with the subsequent risk of pulmonary embolism, is a common adverse effect of thalidomide treatment in patients with multiple myeloma (MM). In our retrospective study, we analyzed candidate single-nucleotide polymorphisms (SNP), CINP (rs7011), CETP (rs289747), ALDH1A1 (rs610529), CDKN1A (rs3829963), GAN (rs2608555), vascular endothelial growth factor...

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Antineoplastic Agents
Share to Genetic Association Studies
Share to Multiple Myeloma
Share to Prognosis
Share to Risk
Share to Thalidomide
Share to Venous Thromboembolism

Source

Identifiers

PMID: 21859556
DOI: 10.1016/j.clml.2011.03.024

Genes

CETP
CINP
GAN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.PMID 21859556Read ↗

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Semantic proximity Read ↗

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.Semantic proximity Read ↗

A review of the venous thrombotic issues associated with multiple myeloma.Semantic proximity Read ↗

Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma.Semantic proximity Read ↗

Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid TumorsSemantic proximity Read ↗

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.Semantic proximity Read ↗

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors.Semantic proximity Read ↗

The role of germline and somatic mutations in predicting cancer-associated thrombosis: a narrative review.Semantic proximity Read ↗

Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.Semantic proximity Read ↗

Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer.Semantic proximity Read ↗

Genetic variations in multiple myeloma II: association with effect of treatment.Semantic proximity Read ↗

VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.